Liisa Hantsoo1, Christian Grillon2, Mary Sammel3, Rachel Johnson3, Joanna Marks4, C Neill Epperson5. 1. Department of Psychiatry & Behavioral Sciences, The Johns Hopkins University School of Medicine, 550 N. Broadway Street, Baltimore, MD, 21205, USA. LHantso1@jhmi.edu. 2. National Institute of Mental Health, 15K North Drive, Bethesda, MD, 20892, USA. 3. Department of Biostatistics and Informatics, Colorado School of Public Health, 13001 E. 17th Place, Mail Stop B119, Aurora, CO, 80045, USA. 4. College of Nursing, Thomas Jefferson University, 130 S. 9th Street, Philadelphia, PA, 19107, USA. 5. Department of Psychiatry, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Abstract
RATIONALE: Women with premenstrual dysphoric disorder (PMDD) appear to have altered central nervous system sensitivity to neuroactive steroid hormones, manifesting as affective symptoms and heightened arousal in the luteal phase of the menstrual cycle. In particular, women with PMDD appear less sensitive to allopregnanolone, a positive allosteric GABA-A receptor (GABA-A-R) modulator. OBJECTIVES: This study evaluated psychophysiologic reactivity in women with PMDD in the follicular and luteal phases of the menstrual cycle, utilizing anxiety-potentiated startle (APS), a potential translational marker of GABA-A-R sensitivity. The study also assessed APS response to low-dose sertraline treatment in women with PMDD. METHODS: Participants' APS and fear-potentiated startle (FPS) were assessed in the follicular and luteal phases. Women with PMDD received 50 mg sertraline in the following luteal phase to examine impact on APS and FPS. RESULTS: There were no significant differences between controls (n = 41) and PMDD participants (n = 36) in change from follicular to luteal phases in baseline startle, APS nor FPS. However, among participants who responded to sertraline, APS was higher in the untreated luteal phase than the follicular phase, but lower in the treated luteal phase than the follicular phase. CONCLUSION: These data demonstrate elevated psychophysiologic arousal in the luteal phase among some women with PMDD, suggesting impaired ability to modulate arousal reactivity. Specifically, alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders.
RATIONALE: Women with premenstrual dysphoric disorder (PMDD) appear to have altered central nervous system sensitivity to neuroactive steroid hormones, manifesting as affective symptoms and heightened arousal in the luteal phase of the menstrual cycle. In particular, women with PMDD appear less sensitive to allopregnanolone, a positive allosteric GABA-A receptor (GABA-A-R) modulator. OBJECTIVES: This study evaluated psychophysiologic reactivity in women with PMDD in the follicular and luteal phases of the menstrual cycle, utilizing anxiety-potentiated startle (APS), a potential translational marker of GABA-A-R sensitivity. The study also assessed APS response to low-dose sertraline treatment in women with PMDD. METHODS: Participants' APS and fear-potentiated startle (FPS) were assessed in the follicular and luteal phases. Women with PMDD received 50 mg sertraline in the following luteal phase to examine impact on APS and FPS. RESULTS: There were no significant differences between controls (n = 41) and PMDD participants (n = 36) in change from follicular to luteal phases in baseline startle, APS nor FPS. However, among participants who responded to sertraline, APS was higher in the untreated luteal phase than the follicular phase, but lower in the treated luteal phase than the follicular phase. CONCLUSION: These data demonstrate elevated psychophysiologic arousal in the luteal phase among some women with PMDD, suggesting impaired ability to modulate arousal reactivity. Specifically, alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders.
Authors: Adam J Devall; Julia M Santos; Jonathan P Fry; John W Honour; Marcus L Brandão; Thelma A Lovick Journal: Eur Neuropsychopharmacol Date: 2014-12-03 Impact factor: 4.600
Authors: T Bäckström; D Haage; M Löfgren; I M Johansson; J Strömberg; S Nyberg; L Andréen; L Ossewaarde; G A van Wingen; S Turkmen; S K Bengtsson Journal: Neuroscience Date: 2011-05-13 Impact factor: 3.590
Authors: Sara K S Bengtsson; Sigrid Nyberg; Helena Hedström; Elisabeth Zingmark; Björn Jonsson; Torbjörn Bäckström; Marie Bixo Journal: Psychoneuroendocrinology Date: 2014-11-08 Impact factor: 4.905
Authors: Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow Journal: Am J Psychiatry Date: 2016-08-13 Impact factor: 18.112
Authors: T Bäckström; M Bixo; M Johansson; S Nyberg; L Ossewaarde; G Ragagnin; I Savic; J Strömberg; E Timby; F van Broekhoven; G van Wingen Journal: Prog Neurobiol Date: 2013-08-23 Impact factor: 11.685